AdAlta Limited Overview
AdAlta is a virtual, clinical-stage Australian biotechnology company that has transformed itself from a single-platform protein-therapeutics discoverer into an "East to West" cell-therapy developer. Its business model is to in-license clinically validated, highly differentiated T-cell therapies for solid cancers from Asian (predominantly Chinese) originators, re-establish their manufacturing in Australia to US FDA standards, run first Western Phase 1 studies under an FDA IND, and then on-license each product to larger biopharmaceutical companies, sharing proceeds with the originator. Its first asset, EW-001 (formerly BZDS1901), is a PD-1-armoured mesothelin CAR-T licensed from Shanghai Cell Therapy Group for all markets outside Greater China, with an FDA pre-IND meeting scheduled for 4 November 2026 (AEST). Legacy i-body assets—Phase 2-ready anti-fibrotic AD-214 and anti-malarial WD-34—are held for partnering. The company is cash-constrained, carries a going-concern qualification and trades as a deep-penny stock.
Company's own description (FY2026 Annual Report)
The FY2026 Annual Report describes AdAlta as a clinical-stage biotechnology business whose principal activity is developing next-generation cellular immunotherapies for solid cancers, together with commercialising protein therapeutics previously discovered on its proprietary i-body® platform. Through the "East to West" strategy, the company states that it integrates Asia's capability in T-cell therapy development with the efficiency and quality of Australia's clinical and manufacturing ecosystem, in-licensing clinically de-risked products from Asian originators, investing to establish FDA-regulated manufacturing and early clinical studies, and positioning each product for on-licensing to larger biopharmaceutical companies for registrational studies and commercialisation. Management describes the model as deliberately capital efficient, designed to return investment on each project within three to four years, and replicable across multiple products.
Independent characterisation
In substance, AdAlta is a development-stage asset aggregator and regulatory/manufacturing "translator" rather than a discovery company. Its value-add sits in the middle of the pharmaceutical value chain:
Upstream (sourcing): screening Asian cell-therapy assets that already have human clinical data in solid tumours. AdAlta uses an in-house AI screening agent ("EMU", built on Anthropic's Claude) to produce referenced preliminary due diligence and score candidates against its selection criteria.
Midstream (value creation): technology transfer of manufacturing to an Australian contract manufacturer (Cell Therapies Pty Ltd, Melbourne), FDA pre-IND engagement (with Dark Horse Consulting Group as regulatory adviser), and first-in-Western-patient Phase 1 studies in Australia, exploiting Australia's comparatively fast and cost-efficient clinical-trial environment and R&D Tax Incentive.
Downstream (monetisation): out-licensing or sale of each asset after Phase 1, with AdAlta entitled to 60% of the proceeds of any commercialisation event following Phase 1 completion for EW-001 (FY2026 Annual Report).
The legacy i-body portfolio (AD-214, WD-34) is now a non-core monetisation pool: management is pursuing out-licensing, spin-out, or grant-funded paths and has ceased internal discovery R&D (February 2025).
Revenue model
| Revenue type | Current status (FY2026) | Commentary |
|---|---|---|
| Product sales | Nil | No approved products |
| Services / collaboration revenue | Nil in FY2025–FY2026 | Historical collaboration income (GE Healthcare, Carina Biotech) appears to have ceased |
| Licensing (out-licensing upfronts/milestones/royalties) | Nil to date | Target monetisation route for AD-214, WD-34 and, post-Phase 1, EW-001 |
| Government grants / tax incentives | A$404,245 R&D Tax Incentive (RDTI) recognised as "other revenue" in FY2026 (FY2025: A$677,010) | The sole recurring inflow; at risk from proposed RDTI changes in the 12 May 2026 federal budget |
| Interest income | A$73,987 (FY2026) | Immaterial |
Customer types and end-markets
There are no customers in a commercial sense. Prospective counterparties are (i) large and mid-sized biopharmaceutical companies seeking Western-validated solid-tumour cell therapies (the eventual licensees of EW-001 and successor assets); (ii) fibrosis-focused pharma (IPF, interstitial lung disease, kidney fibrosis) for AD-214; and (iii) global-health funders, defence/travel-medicine stakeholders and vaccine developers for WD-34. End-markets: oncology (mesothelioma and other mesothelin-expressing cancers such as ovarian, pancreatic and some lung cancers), fibrotic disease, and infectious disease (malaria, babesiosis, toxoplasmosis).
Strategy
Stated strategy (themes from FY2026 Annual Report and 2025 AGM)
-
"East to West" as the key growth driver. The company highlights an "innovation surplus" in Asia—roughly 40% of global cellular immunotherapy developers and 60% of clinical trials are located there—that cannot easily reach Western patients because of data acceptance, transaction cost and supply-chain barriers. AdAlta positions itself as a "force multiplier" that "Westernises" these assets.
-
In-license → add value → exit → recycle. Capital from each exit is recycled into the next asset; the platform is designed to scale across multiple products using public and private capital.
-
Disciplined asset selection. Criteria: solid cancers only; engineered T-cell products; first- or best-in-class potential; existing human clinical proof of concept; closed, scalable, low-cost manufacturing (or a clear path to one).
-
Capital efficiency and asset-level financing. Private financing at AdCella/asset level to fund EW-001 to Phase 1 readout and acquire further assets while limiting parent dilution.
-
Monetise legacy i-body assets (AD-214, WD-34) via partnering, licensing or spin-out.
-
AI-augmented operating model. EMU (Claude-based screening agent) and the Oktopi collaboration extend a two-person team's reach; the Board has adopted oversight principles keeping human experts accountable.
The Chair told the 2025 AGM the company was "on the cusp" of creating a regional leader in cellular immunotherapies.
Initiatives announced in the last 24 months
| Date | Initiative | Type | Target / status |
|---|---|---|---|
| Apr 2024 | Creation of AdCella and AdSolis subsidiaries | Organisational | Done |
| Oct 2024 – Feb 2025 | Three non-binding CAR-T term sheets | Pipeline sourcing | One converted (EW-001) |
| Feb 2025 | Cessation of internal discovery R&D; AD-214 partner-only | Cost program | Done |
| 2,025 | Laboratory closure and asset disposal | Cost program | Done (A$0.11m proceeds) |
| Oct 2025 – Apr 2026 | CEO and NED pay suspension | Cost program | Ended 30 Apr 2026 |
| Jan 2026 | DCA with SHcell for BZDS1901/EW-001 | In-licensing | Initial obligations met |
| Mar 2026 | EW-001 Clinical Advisory Board expansion | Clinical | Done |
| Apr 2026 | First Work Order with Cell Therapies Pty Ltd | Manufacturing | Tech transfer underway; first runs 2H CY2026 |
| Apr 2026 | MoU with Cell Therapies and Oribiotech (IRO® automated platform) | Manufacturing innovation | Deployment targeted CY2027; 10–50x throughput, 30–50% potential cost saving |
| May 2026 | Dark Horse Consulting engaged as regulatory advisers | Regulatory | Pre-IND 4 Nov 2026 |
| Jul 2026 | Oktopi AI collaboration | Digital/AI | Active |
| Jul 2026 | ISCT ANZ 2026 oral presentation and poster | Scientific visibility | Done |
| 2026–2027 | One to two further assets under option or licence | Pipeline | Pending |
| 2026–2027 | WD-34 grant applications / possible spin-out | Monetisation | Pending |
Medium-term targets / guidance
| Timing | Milestone |
|---|---|
| 2H CY2026 | First Australian manufacturing runs of EW-001 at CTPL |
| 2H CY2026 | US FDA pre-IND meeting (confirmed 4 Nov 2026 AEST) |
| CY2026–2027 | One to two further assets secured under option/licence |
| CY2026–2027 | Extended IIT readouts from China |
| CY2027 | Deployment of IRO® automated platform at CTPL |
| 2H CY2027 | First patient dosed in Australian Phase 1 of EW-001 |
| Not forecastable | AD-214 / WD-34 partnering, licensing or spin-out |
No financial guidance is provided (directors withhold likely-developments disclosure as commercially prejudicial). Operational milestone guidance (FY2026 Annual Report):
ESG commitments: formal ESG governance model "being developed"; no quantified targets.
Products & Services
Cellular immunotherapies (AdCella)
| Attribute | Detail |
|---|---|
| Modality | Autologous CAR-T cell therapy (patient's own T cells engineered ex vivo) |
| Target | Mesothelin (MSLN), highly expressed in mesothelioma and >10 other cancers |
| Differentiation | First MSLN CAR-T designed to secrete PD-1-blocking molecules ("armoured"), protecting both infused CAR-T cells and endogenous T cells from tumour immunosuppression; binding tuned to activate only where MSLN is densely expressed (to spare healthy tissue) |
| Manufacturing | Non-viral (transposase-based) process; under two days versus ~nine days for many traditional CAR-Ts; no expensive viral vectors; third-generation faster/lower-cost process being transferred to Cell Therapies Pty Ltd (Melbourne); future automation via Oribiotech IRO® platform; target commercial cost of goods <US$50,000 per patient dose |
| Originator | Shanghai Cell Therapy Group Co Ltd (SHcell), China |
| Rights | Exclusive licence to develop and commercialise outside Greater China (DCA, 2 Jan 2026); exclusive or non-exclusive licences to seven patent families |
| Economics | US$2.0m paid in two milestones (completed by mid-2026); AdAlta receives 60% of proceeds of any commercialisation event after Phase 1; AdCella estimated in January 2026 it could invest A$22–31 million over four years to reach end of Phase 1 (inclusive of upfront and milestones) |
| Clinical data (China IITs, as at July–Oct 2026) | 36 patients across three investigator-initiated trials; at higher doses up to 50% overall response rate and up to 20% complete response rate in second-line-plus advanced mesothelioma; median OS not reached in current-generation process; earlier generation achieved >25 months median OS; one complete responder completed the two-year study assessment without recurrence, second complete responder past one year |
| Comparator benchmarks (cited by company) | Second-line standard therapies: ORR 11–29%, CR almost never, median survival 8–10 months (CONFIRM, CheckMate-743 references) |
| Stage | Pre-IND (Western); FDA pre-IND meeting 4 Nov 2026 AEST; first Australian manufacturing runs targeted 2H CY2026; first Australian Phase 1 patient targeted 2H CY2027 |
| Target customer | Large biopharma licensee post-Phase 1 |
| Pricing | Not disclosed (pre-commercial) |
| Market sizing (company) | Mesothelioma drugs market forecast US$12.2bn by 2034; EW-001 addressable advanced-mesothelioma market ~US$4.2bn before other MSLN+ cancers; >35,000 new mesothelioma cases and >29,000 deaths annually |
EW-001 (formerly BZDS1901)
Pipeline candidates (unnamed): additional CAR-T/engineered T-cell assets in due diligence; stated aspiration to progress one new asset into the clinic each year and secure one to two further assets under option or licence in CY2026–2027. Three non-binding term sheets had been executed by February 2025; none besides EW-001 has been publicly converted to a definitive licence.
i-body® enabled protein therapeutics
| Attribute | Detail |
|---|---|
| Modality | First-in-class i-body Fc-fusion protein |
| Target | CXCR4 (G-protein-coupled receptor) |
| Indications | Idiopathic pulmonary fibrosis (IPF), interstitial lung disease, kidney fibrosis; historical exploration of eye fibrosis and inhaled formulation |
| Clinical status | Two successful Phase I studies (single ascending dose IV in healthy volunteers; Phase I extension establishing tolerability of planned Phase 2 dose of 10 mg/kg IV every two weeks); low-level anti-drug antibodies without PK/PD impact; declared Phase 2-ready |
| IP | Composition-of-matter patents granted in Australia, US, Europe, China, Japan, India, Singapore and Canada, expiring 8 January 2036; method-of-treatment applications could extend to 2043 |
| Commercial path | Out-licence (lung and/or kidney) or spin-out financing of Phase 2; most recent inbound interest focused on kidney fibrosis |
| Competitive context | Boehringer Ingelheim's nerandomilast (Jascayd) approved by FDA for IPF (Oct 2025) and progressive pulmonary fibrosis (Dec 2025), per company |
| Attribute | Detail |
|---|---|
| Modality | i-body (discovery stage), discovered with La Trobe University |
| Target | Conserved region of AMA1 (apical membrane antigen 1) |
| Profile | Pan-species recognition of Plasmodium species plus Babesia and Toxoplasma; high-potency inhibition of parasite invasion |
| Potential uses | Long-acting single-dose prophylaxis (travellers, military), seasonal malaria chemoprevention for children, antigen generation for vaccines |
| Status | Seeking grant/third-party funding for format optimisation and pre-clinical proof of concept; possible dedicated spin-out; patent applications lodged |
AD-214
WD-34
Legacy / discontinued programs: GE Healthcare granzyme B i-body PET imaging agents (collaboration active through at least FY2023; current status not publicly disclosed); Carina Biotech i-body-directed CAR-T collaboration (five solid-tumour antigens; current status not publicly disclosed); internal i-body discovery (ceased February 2025).
Enabling capabilities
| Capability | Description |
|---|---|
| EMU | In-house AI agent built on Anthropic's Claude for referenced due diligence and asset scoring |
| Oktopi collaboration (July 2026) | AI-enabled platform to peer-review development plans and expert decisions |
| i-body platform | Human protein scaffold libraries (>2 billion compounds at IPO) mimicking shark single-domain antibodies |
Financial Narrative
Blank cells = not publicly disclosed in sources reviewed or not meaningful.
Income statement
Gross profit, operating income, EBITDA and pre-tax income margins are not meaningful in the absence of revenue. EBITDA ≈ operating loss given negligible depreciation (FY2026 depreciation nil; FY2025 A$0.085m). Pre-tax income equals net loss (no tax expense; ~A$23.8m of unrecognised revenue tax losses at 30 June 2026). Revenue CAGR: not meaningful.
Balance sheet
Notes: FY2024 long-term debt (A$1.321m) per InvestSMART relates to the NLSC/Meurs institutional investment liability; FY2024 also carried the Treasury Corporation of Victoria R&D loan (A$1.40m, repaid October 2024). FY2026 "other current liabilities" of A$0.82m are share-application monies (A$0.795m for shares requiring the 15 June 2026 EGM approval, issued 2 July 2026, plus A$25k to be refunded) and are not debt.
Cash flow
FY2026 equity raised gross = A$4.512m share proceeds + A$0.820m share monies requiring approval. FY2025 investing inflow reflects disposal of laboratory plant and equipment (A$0.110m) after laboratory closure.
Ratios
ROE, ROIC, interest coverage, asset turnover and cash conversion cycle are not meaningful (negative/near-zero equity, no revenue, no invested operating capital). ROA computed on average total assets. FY2025 debt/equity is undefined due to negative equity (−A$0.598m).
Commentary on trends, inflections and drivers
Loss trajectory. Net losses have been remarkably stable in the A$4.5–6.1 million band across five years, but the composition has changed fundamentally. FY2022–FY2024 losses funded an in-house laboratory, AD-214 clinical studies and platform discovery; FY2026's A$4.68 million loss is dominated by a single non-recurring item—A$2.858 million of EW-001 licence/milestone payments to SHcell—with underlying operating costs collapsing. Corporate administration (external) halved from A$2.12m to A$1.02m, and employee costs across R&D and admin fell from A$1.30m to A$0.26m, reflecting laboratory closure, a two-person permanent workforce, and the suspension of CEO pay (November 2025–April 2026) and non-executive director fees (October 2025–April 2026).
Liquidity is the binding constraint. Cash has declined monotonically from A$8.66m (FY2022) to A$1.28m (FY2026). The FY2026 cash balance was almost unchanged from FY2025 only because A$5.3m of equity was raised across three placements. With the US$2.0m DCA commitment now satisfied, the run-rate burn should fall, but the company's own January 2026 estimate of A$22–31m to take EW-001 through Phase 1 vastly exceeds its balance sheet. Management's intended solution is asset-level (AdCella) private financing to limit dilution at the listed parent.
Balance sheet clean-up. FY2026 saw the elimination of all interest-bearing and convertible obligations: the Radium Capital RDTI advance (16% p.a.) was repaid in December 2025, and the NLSC/Meurs institutional investment liability (A$1.38m at FY2025) was extinguished through A$1.201m of conversions into 667 million shares and A$0.407m of cash repayment. This restored positive equity (A$0.37m) and net tangible assets per share of 0.01–0.02 cents, but at the cost of severe dilution.
Dilution. Shares on issue rose from ~596 million (FY2024) to ~1,071 million (FY2025) to ~2,976 million (FY2026) and ~3,212 million after the July 2026 issue—a more than fivefold increase in two years—while ~1.08 billion A$0.01 listed options overhang the register. Weighted-average shares tripled in FY2026, which is why EPS improved from −0.69c to −0.23c despite a larger loss.
RDTI dependence. RDTI refunds historically funded a third or more of annual burn (A$2.08m for FY2022, A$2.35m for FY2023, A$1.77m for FY2024). The FY2026 receivable is only A$0.22m because most spend was offshore licence payments (an Overseas Finding application is pending which could increase it). The 12 May 2026 federal budget proposals could materially reduce and delay future RDTI benefits, per the Annual Report.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Business Units
| Business unit (management view) | Legal vehicle | Contents | Status |
|---|---|---|---|
"East to West" cellular immunotherapies | AdCella Pty Ltd (subsidiary; created April 2024) | EW-001 (formerly BZDS1901) mesothelin CAR-T; pipeline of further in-licensing candidates in due diligence | Core growth driver |
i-body® enabled assets | AdAlta Limited / AdSolis Pty Ltd (created April 2024) | AD-214 (fibrosis), WD-34 (malaria), residual i-body IP | Partnering / spin-out only |
Results by Segment and Segment Margins & Growth (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Revenue and other income - single segment (AUD Mn) | 1.738 | 0.696 | 0.478 |
Of which RDTI income (AUD Mn) | — | 0.677 | 0.404 |
Loss before tax - single segment (AUD Mn) | -5.381 | -4.502 | -4.684 |
YoY change in loss (%) | 10.9 | -16.3 | 4.0 |
Revenue by Segment
| Metric | FY2025 | FY2026 |
|---|---|---|
R&D expense external (AUD Mn) | 1.336 | 3.212 |
R&D employee benefits (AUD Mn) | 0.860 | 0.124 |
Corporate admin external (AUD Mn) | 2.119 | 1.018 |
Corporate admin employee benefits (AUD Mn) | 0.444 | 0.137 |
Patent and legal (AUD Mn) | 0.220 | 0.275 |
Finance costs (AUD Mn) | 0.062 | 0.291 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from customers (AUD Mn) | — | — | — | 0 | 0 |
Revenue and other income incl RDTI (AUD Mn) | 2.754 | 3.469 | 1.738 | 0.696 | 0.478 |
Total expenses (AUD Mn) | — | — | — | 5.198 | 5.162 |
R&D expense total (AUD Mn) | — | — | — | 2.196 | 3.336 |
Net loss after tax (AUD Mn) | -6.061 | -4.851 | -5.381 | -4.502 | -4.684 |
Basic EPS (AUD cents) | — | -1.3 | -0.9 | -0.69 | -0.23 |
Diluted EPS (AUD cents) | — | -1.3 | -0.9 | -0.69 | -0.23 |
Dividends per share (AUD cents) | 0 | 0 | 0 | 0 | 0 |
Weighted avg shares (M) | — | — | — | 653.1 | 2,047.7 |
Balance Sheet and Share Count (M)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash and equivalents (AUD Mn) | 8.661 | 4.790 | 3.133 | 1.306 | 1.284 |
Trade and other receivables (AUD Mn) | — | — | — | 0.836 | 0.437 |
Total assets (AUD Mn) | — | — | — | 2.142 | 1.722 |
Short-term debt (AUD Mn) | — | — | — | 0.447 | 0 |
Long-term debt and financial liabilities (AUD Mn) | — | — | 1.321 | 1.376 | 0 |
Total debt (AUD Mn) | — | — | — | 1.823 | 0 |
Net debt (AUD Mn) | — | — | — | 0.517 | -1.284 |
Total liabilities (AUD Mn) | — | — | — | 2.740 | 1.351 |
Shareholders equity (AUD Mn) | — | 1.9 | 2.030 | -0.598 | 0.370 |
Goodwill and intangibles (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Working capital (AUD Mn) | — | — | — | 0.805 | 0.370 |
Accumulated losses (AUD Mn) | — | — | 47.520 | 52.023 | 56.706 |
Shares on issue year end (M) | — | — | 595.6 | 1,071.3 | 2,975.9 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (AUD Mn) | -4.089 | -5.132 | -5.260 | -2.937 | -4.440 |
Investing cash flow (AUD Mn) | -0.025 | -0.002 | -0.062 | 0.110 | 0 |
Capex (AUD Mn) | 0.025 | 0.002 | 0.062 | 0 | 0 |
Free cash flow (AUD Mn) | -4.114 | -5.134 | -5.322 | -2.937 | -4.440 |
Financing cash flow (AUD Mn) | 7.023 | 1.267 | 3.666 | 0.999 | 4.419 |
Equity raised gross (AUD Mn) | — | — | — | 1.284 | 5.332 |
RDTI cash received in year (AUD Mn) | — | — | — | 1.775 | 0.934 |
Dividends paid (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Buybacks (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Financial Ratios (x) and Returns & Leverage Ratios (%)
| Metric | FY2025 | FY2026 |
|---|---|---|
Current ratio (x) | 1.60 | 1.27 |
Debt to equity (x) | — | 0 |
ROA (%) | -233 | -242 |
Cash burn per quarter avg (AUD Mn) | 0.73 | 1.11 |
Revenue by Region
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Australia revenue and other income (AUD Mn) | 1.738 | 0.696 | 0.478 |
Americas revenue (AUD Mn) | 0 | 0 | 0 |
EMEA revenue (AUD Mn) | 0 | 0 | 0 |
Asia ex-Australia revenue (AUD Mn) | 0 | 0 | 0 |
Capital Markets
| Item | Detail |
|---|---|
Latest verified price | A$0.003–0.004 (InvestSMART, June–July 2026; announcement-date prices through Q3 2026 at ~A$0.004) |
52-week range | A$0.0017 – A$0.008 (Stocklight) |
Market cap (approx.) | A$10–13m on ~3.21bn shares |
Listed options | 1ADO: ~1.08bn, A$0.01 exercise, expiry 3 Jun 2028 (deeply out of the money at ~2.5–3x current price) |
Index membership | None identified |
Dividend history / policy | No dividends ever paid; none expected |
Credit ratings (Moody's/S&P/Fitch) | Not rated |
Debt maturity profile | No debt outstanding at 30 June 2026 |
Capital Markets — Price change
| Metric | 1-year | 3-year |
|---|---|---|
Price change (%) | Approximately flat to down (A$0.003–0.005 range through 2025–2026) | Approximately −80% to −85% (≈A$0.02 in late 2023 to ≈A$0.003–0.004) |
Share Count (M) and Margin Analysis (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Shares on issue year end (M) | 595.6 | 1,071.3 | 2,975.9 |
Annual shareholder return (%) | 8.4 | -90.8 | — |
Equity issued for cash in year (AUD Mn) | — | 1.284 | 4.512 |
Valuation Multiples
| Multiple | AdAlta | Comment |
|---|---|---|
P/E | n/m | Loss-making |
EV/EBITDA | n/m | Negative EBITDA |
EV/Sales | n/m | No revenue |
P/B | ~27–35x | Market cap A$10–13m vs equity A$0.37m (FY2026); not meaningful given tiny book |
EV (approx.) | ~A$9–12m | Market cap less ~A$1.3m cash, zero debt |
Analyst Conclusions
Management guidance
No financial guidance. Operational guidance: first Australian EW-001 manufacturing runs and FDA pre-IND meeting in 2H CY2026 (pre-IND confirmed 4 Nov 2026 AEST, minutes 2–4 weeks later); one to two additional assets in CY2026–2027; IRO® deployment CY2027; first Australian Phase 1 patient 2H CY2027. Consensus growth expectations: none available.
Bull case
-
Differentiated clinical signal: complete responses (up to 20%) and durable two-year disease-free survival in a refractory solid tumour are rare; if replicated in an FDA-grade Australian Phase 1, EW-001 could command a meaningful licence deal, of which AdAlta retains 60% of proceeds.
-
Low-cost model with optionality: a two-person, debt-free virtual company with an EV of roughly A$10m holds a pre-IND CAR-T, a Phase 2-ready anti-fibrotic with patents to 2036+, and a novel anti-malarial—each partnering event could rerate the stock.
-
Manufacturing moat: a non-viral <2-day process plus automation targeting <US$50k COGS addresses the main commercial objection to CAR-T, enhancing attractiveness to big pharma.
Bear case
-
Funding gap: A$1.28m cash versus A$22–31m to reach Phase 1 readout; absent asset-level financing, further heavily dilutive raises at sub-cent prices are likely, on top of ~1.08bn options.
-
Data fragility: 36 patients in non-randomised Chinese IITs; the October 2026 update revealed progression in two of five recently followed patients; FDA may require substantial additional work.
-
Execution and geopolitical concentration: dependence on a single Chinese originator (approvals via JDC, materials supply) and a single CDMO amid US–China tensions, with only two employees and a four-person board.
Key catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable |
|---|---|
| Late Oct 2026 | September-quarter 4C: cash position and burn |
| 4 Nov 2026 | FDA pre-IND meeting; minutes ~late Nov–Dec 2026 |
| 2H CY2026 | First CTPL manufacturing runs and comparability data |
| Nov 2026 | 2026 AGM (possible capital structure resolutions, e.g., consolidation or placement capacity) |
| Q1 CY2027 | Next IIT assessments (second CR at 18 months; stable-disease patient) |
| CY2026–2027 | AdCella asset-level financing; new asset in-licence |
| Feb 2027 | H1 FY2027 report |
| Any time | AD-214 / WD-34 partnering; RDTI legislative outcome; Hainan special-access patient treatment |
Analyst verdict
AdAlta in October 2026 is a fundamentally different company from the i-body discovery platform that listed in 2016. Management has executed a disciplined, if painful, pivot: it shut the laboratory, cut fixed costs to a two-person core, retired every interest-bearing and convertible liability, and converted a strategic thesis—bringing Asian cell-therapy innovation through Western regulatory and manufacturing pathways—into a signed, fully paid-up licence for a genuinely interesting asset. EW-001's complete responses and two-year disease-free survival in relapsed mesothelioma are the kind of signal that cell-therapy business-development teams notice, and its non-viral, rapid manufacturing process speaks directly to the economics that have constrained CAR-T commercially. The FDA's acceptance of a pre-IND meeting within nine months of licensing is tangible evidence that the "East to West" machinery works.
The problem is not the strategy but the balance sheet. With A$1.28 million of cash at year-end, a going-concern qualification for three consecutive years, more than 3.2 billion shares on issue and over a billion options overhanging the register, the listed entity has limited capacity to fund a program it has itself costed at A$22–31 million. Value accretion for existing shareholders therefore depends heavily on securing non-dilutive or asset-level capital (AdCella financing, AD-214 licensing, grants) and on a constructive FDA outcome on 4 November. The October update showing progression in two recently followed patients is a reminder that the clinical dataset is small and immature.
On balance, AdAlta is a high-risk, binary, catalyst-driven micro-cap. The scientific and strategic logic is credible and management execution in 2026 has been on schedule, but the probability-weighted outcome for equity holders is dominated by financing terms. Investors should treat the stock as a speculative option on EW-001's Western translation, with the FDA minutes and the next financing structure as the decisive near-term signals.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Background / education | Independence |
|---|---|---|---|---|
Dr Paul MacLeman | Non-Executive Chair (formerly Executive Chair) | 16 Apr 2015 |
| Non-executive; long tenure (>11 years) may challenge independence under ASX Principles |
Dr Timothy Oldham | CEO & Managing Director | Board 8 Oct 2019 | Former CEO/MD Cell Therapies Pty Ltd; President Asia Pacific, Hospira; senior roles at Mayne Pharma; McKinsey engagement manager; Executive Leader Tijan Ventures. NED Acrux (ASX:ACR); Chair Skin2Neuron. BSc(Hons), LLB(Hons), PhD | Executive |
Ms Michelle Burke | Non-Executive Director; Chair of Remuneration & Nomination Committee | 20 Nov 2024 |
| Non-executive; potential conflict given Cell Therapies is AdAlta's contract manufacturer |
Mr Fadi Diab | Non-Executive Director | 18 Mar 2026 |
| Non-executive |
Dr David Fuller | Former NED | 22 Jul 2020 – 17 Apr 2026 | MBBS, BPharm(Hons) | Resigned |
Directors' Remuneration
| Item | Detail |
|---|---|
Board size | 4 (3 NEDs + CEO) at 30 June 2026 |
Chair / CEO separation | Yes (separate individuals) |
Committees | Remuneration & Nomination (Burke – Chair, MacLeman, Diab); Audit & Risk (composition per Corporate Governance Statement; all NEDs invited) |
FY2026 meetings | Board 10; Rem & Nom 2; Audit & Risk 1 |
Gender | 1 of 3 NEDs female; both permanent employees male |
NED fee pool | A$350,000 approved; current fees A$75,000 (Chair), A$50,000 (NEDs); no committee fees |
2025 AGM remuneration report vote |
|
Directors' Remuneration by Name
| Name | Cash salary/fees (AUD) | Super (AUD) | Share-based (AUD) | Total earned (AUD) |
|---|---|---|---|---|
Dr Timothy Oldham (CEO & MD) | 177,825 | 13,679 | 10,468 | 201,972 |
Dr Paul MacLeman (Chair) | 25,893 | 5,357 | 3,383 | 34,633 |
Ms Michelle Burke | 17,262 | 3,571 | 0 | 20,833 |
Mr Fadi Diab | 8,333 | 0 | 0 | 8,333 |
Dr David Fuller (resigned) | 12,500 | 0 | 2,114 | 14,614 |
Total KMP | 241,813 | 22,607 | 15,965 | 280,385 |
Directors' Shareholdings
| Director | Ordinary shares | Unlisted options | Listed options (1ADO) |
|---|---|---|---|
Dr Timothy Oldham | 17,265,415 | 6,357,195 | 5,833,333 |
Dr Paul MacLeman | 544,042 | 2,800,000 | 35,536 |
Ms Michelle Burke | 0 | 0 | 0 |
Mr Fadi Diab | 0 | 0 | 0 |
Major Shareholders
| Holder | Shares | % at notice date |
|---|---|---|
Stuart Morris (and associated entities) | 166,108,388 | 14.92 |
HSBC Custody Nominees (Australia) Limited | 92,345,364 | 8.30 |
Chunyan Niu | 66,666,667 | 5.99 |
Competitive Landscape
Key Competitors
| Competitor | Segment | Relevance / positioning vs AdAlta |
|---|---|---|
CARsgen Therapeutics (China/HK-listed) | Solid-tumour CAR-T | Chinese CAR-T leader with solid-tumour programs; a reference point for the first solid-tumour CAR-T approvals in China |
Adaptimmune / former TCR2 Therapeutics (gavo-cel) | Mesothelin-targeted T-cell therapy | Historical MSLN TCR-fusion program in mesothelioma; demonstrates target validity and also development risk |
Atara Biotherapeutics | Mesothelin CAR-T (allogeneic/armoured) | Prior MSLN CAR-T programs |
Memorial Sloan Kettering-derived academic MSLN CAR-T programs | Mesothelioma CAR-T | Academic competition for mesothelioma trial patients |
Carina Biotech (private, Adelaide) | Solid-tumour CAR-T | Former AdAlta collaborator; Australian competitor for capital and clinical sites |
Chimeric Therapeutics (ASX: CHM) | Solid-tumour CAR-T | ASX peer competing for the same retail/biotech capital pool |
Imugene (ASX: IMU) | CAR-T (azer-cel, onCARlytics) | ASX peer in cell therapy |
Prescient Therapeutics (ASX: PTX) | OmniCAR / CellPryme platforms | ASX peer |
Arovella Therapeutics (ASX: ALA) | iNKT cell therapy | ASX peer |
Western "NewCo" in-licensors of Chinese assets (numerous US-based, venture-backed) | In-licensing | Compete for the best Chinese assets with deeper capital |
Large pharma (e.g., AstraZeneca, BMS, Novartis) | Direct China in-licensing | Can buy assets directly, bypassing intermediaries |
Boehringer Ingelheim (nintedanib; nerandomilast/Jascayd) | IPF / PPF | Incumbent standards of care competing with AD-214 |
Roche (pirfenidone) | IPF | Incumbent standard of care |
Bristol Myers Squibb (admilparant, LPA1 antagonist) | IPF pipeline | Late-stage competitor |
GSK / Sanofi malaria franchises; long-acting monoclonal antibody programs (e.g., NIH-derived L9LS) | Malaria prophylaxis | Competing approaches to WD-34 |
Peer Comparison FY2026
| Metric | AdAlta FY2026 | Peer comparison |
|---|---|---|
Revenue | Nil | Most ASX cell-therapy peers also pre-revenue |
Net loss (AUD Mn) | 4.68 | — |
Cash (AUD Mn) | 1.28 | — |
R&D intensity | n/m | n/m |
Market cap (AUD Mn, approx.) | 10–13 | — |



